| 180 | 0 | 1418 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 探讨碳离子治疗头颈部腺样囊性癌（adenoid cystic carcinoma，ACC）的优势。方法 回顾性报道2020年3月至2021年6月在甘肃省武威肿瘤医院武威重离子中心（Wuwei Heavy Ion Center，WWHIC）接受碳离子放疗的5例头颈部ACC患者的病例资料，分析治疗疗效和不良反应。碳离子剂量定义为物理剂量乘以碳离子相对生物学有效性（relative biological effectiveness，RBE），用Gy（RBE）表示，均为RBE为3.0时的剂量。靶区处方剂量为64.0~68.0 Gy（RBE）/16~17 Fx。结果 5例患者均完成碳离子治疗，平均随访16.6个月（13~20个月）。随访至12个月时，1例达到完全缓解（complete response，CR），3例达到部分缓解（partial response，PR），1例因治疗后6个月出现肺部转移评价为疾病进展（progressive disease，PD）。1年总生存（overall survival，OS）率为100.0%，1年局部控制（local control，LC）率为100.0%，1年无进展生存（progression-free survival，PFS）率为80.0%。1例发生2级急性口腔黏膜反应。1例发生1级口干的放疗晚期不良反应。所有患者均未发生≥3级不良反应。结论 碳离子放疗应用于不可手术切除、术后残留及复发的头颈部ACC可获得良好的OS和LC，且不良反应可耐受。
Abstract：[1] Coca-Pelaz A, Rodrigo JP, Bradley PJ, et al. Adenoid cystic carcinoma of the head and neck:an update[J]. Oral Oncol, 2015, 51(7):652-661.
[2] 邱明珠, 徐宝卿, 汤晓晖, 等. 涎腺腺样囊性癌40例临床病理特征及预后分析[J]. 临床与实验病理学杂志, 2021, 37(4):428-433.
[3] Unsal AA, Chung SY, Zhou AH, et al. Sinonasal adenoid cystic carcinoma:a population-based analysis of 694 cases[J]. Int Forum Allergy Rhinol, 2017, 7(3):312-320.
[4] Atallah S, Casiraghi O, Fakhry N, et al. A prospective multicentre REFCOR study of 470 cases of head and neck adenoid cystic carcinoma:epidemiology and prognostic factors[J]. Eur J Cancer, 2020, 130:241-249.
[5] 杨子桧. CCL2/CCR2分子轴在涎腺腺样囊性癌嗜神经侵袭中的作用及机制研究[D]. 西安:中国人民解放军空军军医大学, 2019.
[6] Cantù G. Adenoid cystic carcinoma. An indolent but aggressive tumour. Part B:treatment and prognosis[J]. Acta Otorhinolaryngol Ital, 2021, 41(4):296-307.
[7] 李燕, 邓文英, 李宁, 等. 头颈部腺样囊性癌的临床特征治疗策略和预后[J]. 中华肿瘤杂志, 2019, 41(12):932- 936.
[8] Rodriguez-Russo CA, Junn JC, Yom SS, et al. Radiation therapy for adenoid cystic carcinoma of the head and neck[J]. Cancers, 2021, 13(24):6335.
[9] 杨婧艺, 王德辉. 鼻腔鼻窦腺样囊性癌治疗进展[J]. 中国眼耳鼻喉科杂志, 2019, 19(4):287-292.
[10] Zhang Q, Kong L, Liu R, et al. Chinese ion therapy guideline (Version 2020)[J]. Precis Radiat Oncol, 2021, 11(3):1-11
[11] Freites-Martinez A, Santana N, Arias-Santiago S, et al. Using the common terminology criteria for adverse events (CTCAE-version 5.0) to evaluate the severity of adverse events of anticancer therapies[J]. Actas Dermosifiliogr, 2021, 112(1):90-92.
[12] Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)[J]. Int J Radiat Oncol Biol Phys, 1995, 31(5):1341-1346.
[13] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2):240-247.
[14] Ouyang DQ, Liang LZ, Zheng GS, et al. Risk factors and prognosis for salivary gland adenoid cystic carcinoma in southern China:a 25-year retrospective study[J]. Medicine, 2017, 96(5):e5964.
[15] 钟江 涛, 周水 洪. 2023年 第1 版《NCCN头颈 部癌 临床实践指南》更新解读[J]. 实用肿瘤杂志, 2023, 38(3):203-210.
[16] Grimes DR. Estimation of the oxygen enhancement ratio for charged particle radiation[J]. Phys Med Biol, 2020, 65(15):15NT01.
[17] Kamada T, Tsujii H, Blakely EA, et al. Carbon ion radiotherapy in Japan:an assessment of 20 years of clinical experience[J]. Lancet Oncol, 2015, 16(2):e93-100.
[18] Mizoe JE, Tsujii H, Kamada T, et al. Dose escalation study of carbon ion radiotherapy for locally advanced head-andneck cancer[J]. Int J Radiat Oncol Biol Phys, 2004, 60(2):358-364.
[19] Koto M, Hasegawa A, Takagi R, et al. Evaluation of the safety and efficacy of carbon ion radiotherapy for locally advanced adenoid cystic carcinoma of the tongue base[J]. Head Neck, 2016, 38(1_suppl):E2122-2126.
[20] Sulaiman NS, Demizu Y, Koto M, et al. Multicenter study of carbon-ion radiation therapy for adenoid cystic carcinoma of the head and neck:subanalysis of the Japan Carbon-ion Radiation Oncology Study group (J-CROS) study (1402 HN)[J]. Int J Radiat Oncol, 2018, 100(3):639-646.
[21] Morimoto K, Demizu Y, Hashimoto N, et al. Particle radiotherapy using protons or carbon ions for unresectable locally advanced head and neck cancers with skull base invasion[J]. Jpn J Clin Oncol, 2014, 44(5):428-434.
[22] Takagi M, Demizu Y, Hashimoto N, et al. Treatment outcomes of particle radiotherapy using protons or carbon ions as a single-modality therapy for adenoid cystic carcinoma of the head and neck[J]. Radiother Oncol, 2014, 113(3):364-370.
[23] Schulz-Ertner D, Nikoghosyan A, Thilmann C, et al. Results of carbon ion radiotherapy in 152 patients[J]. Int J Radiat Oncol Biol Phys, 2004, 58(2):631-640.
[24] Hayashi K, Koto M, Ikawa H, et al. Feasibility of re-irradiation using carbon ions for recurrent head and neck malignancies after carbon-ion radiotherapy[J]. Radiother Oncol, 2019, 136:148-153.
[25] Chen J, Mao JF, Ma NY, et al. Definitive carbon ion radiotherapy for tracheobronchial adenoid cystic carcinoma:a preliminary report[J]. BMC Cancer, 2021, 21(1):734.
[26] Lang K, Adeberg S, Harrabi S, et al. Adenoid cystic Carcinoma and Carbon ion Only irradiation (ACCO):study protocol for a prospective, open, randomized, two-armed, phase Ⅱ study[J]. BMC Cancer, 2021, 21(1):812.
[27] Loap P, Vischioni B, Bonora M, et al. Biological rationale and clinical evidence of carbon ion radiation therapy for adenoid cystic carcinoma:a narrative review[J]. Front Oncol, 2021, 11:789079.
基本信息:
DOI：10.13267/j.cnki.syzlzz.2024.027
引用信息:
[1]李小军1,柴鸿钰1,张雁山1,等.碳离子治疗头颈部腺样囊性癌疗效观察并文献复习[J],2024,39(02):170-175.DOI:10.13267/j.cnki.syzlzz.2024.027.
基金信息:
甘肃省省级科技计划项目（基础研究计划-自然科学基金）（22JR5RH1036）；武威市2020年度第二批市列科技计划资助项目（ww2002050）